学校法人順天堂　研究者情報データベース:::研究業績詳細:::

HOME　＞　研究業績詳細

研究業績詳細

森本真司（モリモトシンジ）

研究テーマ	膠原病、特に全身性エリテマトーデスの病態における免疫機構の解析
研究業績（論文）	１なし、２なし、３なし、４なし、５なし、６．論文 1. Hatano R, Nakamura H, Yamamoto A, Otsuka H, Itoh T, Hosokawa N, Yu J, Ranjbar S, Hasegawa Y, Sato T, Dang NH, Ohnuma K, Morimoto S, Sekigawa I, Ishii T, Morimoto C. An abnormal increase in CD26(−)CD28(−) cytotoxic effector CD4 and CD8 T cell populations in patients with systemic lupus erythematosus. Int Immunol. 2025; 37(3):153–171. 2. Suzuki S, Otani T, Ikeda K, Tamura N, Morimoto S. Immunol Method. Additional benefits of belimumab in chronic phase of systemic lupus erythematosus and efficacy of tacrolimus combination therapy2024 Dec 27:1-7. doi: 10.1080/25785826.2024.2447629. 3. Suzuki S, Kataoka Y, Otani T, Taniguchi Y, Ikeda K, Tamura N, Morimoto S. Optimal time of starting tocilizumab in acute phase of adult-onset Still's disease and comparison of its efficacy with that of methotrexate: a case series and a review of the literature Clin Rheumatol. 2024 43(3):1245-1251. 4. Hayakawa K, Fujishiro M, Yoshida Y, Kataoka Y, Sakuma S, Nishi T, Ikeda K, Morimoto S, Takamori K, Sekigawa I. Exposure of female NZBWF1 mice to imiquimod-induced lupus nephritis at an early age via a unique mechanism that differed from spontaneous onset. Clin Exp Immunol. 2022 13;208(1):33-46. 5. Suzuki S, Ikeda K, Yamaji K, Tamura N, Morimoto S. Recurrence in long-term survivor of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis: case series and literature review Mod Rheumatol Case Rep. 2021 5(2):310-316. 6. Kogami M, Suzuki S, Nanjo Y, Ikeda K, Tamura N, Sasaki S, Morimoto S. Complication of coronavirus disease 2019 during remission induction therapy against anti-MDA5 antibody-positive dermatomyositis　Rheumatol Adv Pract. 2020 17;4(2):rdoi: 10.1093/rap/rkaa068. 7. Yoshida Y, Hayakawa K, Fujishiro M, Ikeda K, Tsushima H, Hirai T, Kawasaki M, Tominaga M, Suga Y, Takamori K, Watanabe Y, Sekigawa I, Morimoto S. Social defeat stress exacerbates atopic dermatitis through downregulation of DNA methyltransferase 1 and upregulation of C-C motif chemokine receptor 7 in skin dendritic cells. Biochem Biophys Res Commun. 2020;529(4):1073-9. 8. Matsuoka Y, Morimoto S, Fujishiro M, Hayakawa K, Kataoka Y, Suzuki S, Ikeda K, Takamori K, Yamaji K, Tamura N. Metformin repositioning in rheumatoid arthritis. Clin Exp Rheumatol. 2020. 9. Hayakawa K, Kawasaki M, Hirai T, Yoshida Y, Tsushima H, Fujishiro M, Ikeda K, Morimoto S, Takamori K, Sekigawa I. MicroRNA-766-3p Contributes to Anti-Inflammatory Responses through the Indirect Inhibition of NF-kappaB Signaling. Int J Mol Sci. 2019;20(4). 10. Niimi N, Miyashita T, Tanji K, Hirai T, Watanabe K, Ikeda K, Morimoto S, Sekigawa I. Aortic Aneurysm as a Complication of Granulomatosis with Polyangiitis Successfully Treated with Prednisolone and Cyclophosphamide: A Case Report and Review of the Literature. Case Rep Rheumatol. 2018;2018:9682801. 11. Ikeda K, Sekiguchi N, Hirai T, Tanji K, Zushi A, Inoue M, Takasago M, Komatsu T, Morimoto S, Yamaji K, Takamori K, Tamura N, Sekigawa I. Securely collecting multidimensional health information from patients with rheumatoid arthritis using smart device technology: Beneficial effect for physicians and patients. Musculoskeletal Care. 2018;16(4):494-9. 12. Hirai T, Ikeda K, Tsushima H, Fujishiro M, Hayakawa K, Yoshida Y, Morimoto S, Yamaji K, Takasaki Y, Takamori K, Tamura N, Sekigawa I. Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis. Inflamm Regen. 2018;38:1. 13. Hayakawa K, Ikeda K, Fujishiro M, Yoshida Y, Hirai T, Tsushima H, Miyashita T, Morimoto S, Suga Y, Takamori K, Ogawa H, Sekigawa I. Connective Tissue Growth Factor Neutralization Aggravates the Psoriasis Skin Lesion: The Analysis of Psoriasis Model Mice and Patients. Ann Dermatol. 2018;30(1):47-53. 14. Tsushima H, Morimoto S, Fujishiro M, Yoshida Y, Hayakawa K, Hirai T, Miyashita T, Ikeda K, Yamaji K, Takamori K, Takasaki Y, Sekigawa I, Tamura N. Kinase inhibitors of the IGF-1R as a potential therapeutic agent for rheumatoid arthritis. Autoimmunity. 2017;50(5):329-35. 15. Sugiura-Ogasawara M, Omae Y, Kawashima M, Toyo-Oka L, Khor SS, Sawai H, Horita T, Atsumi T, Murashima A, Fujita D, Fujita T, Morimoto S, Morishita E, Katsuragi S, Kitaori T, Katano K, Ozaki Y, Tokunaga K. The first genome-wide association study identifying new susceptibility loci for obstetric antiphospholipid syndrome. J Hum Genet. 2017;62(9):831-8. 16. Miyashita T, Morimoto S, Honda D, Nakano S, Amano H, Osawa I, Yamaji K, Tomino Y, Takasaki Y, Tamura N. Outcomes of the Re-classification of WHO Class IV Lupus Nephritis Using the ISN/RPS Classification: a Single Center Retrospective Observational Study from the JUDE Study. Juntendo Medical Journal. 2017;63(5):362-9. 17. Minowa K, Amano H, Ando S, Watanabe T, Ogasawara M, Kawano S, Kaneko T, Morimoto S, Yamaji K, Tamura N, Tokano Y, Hashimoto H, Takasaki Y. Disease flare patterns and predictors of systemic lupus erythematosus in a monocentric cohort of 423 Japanese patients during a long-term follow-up: The JUDE study. Mod Rheumatol. 2017;27(1):72-6. 18. Ikeda K, Watanabe K, Hirai T, Tanji K, Miyashita T, Nakajima S, Uomori K, Morimoto S, Takamori K, Ogawa H, Takasaki Y, Sekigawa I. Mizoribine Synchronized Methotrexate Therapy should be Considered when Treating Rheumatoid Arthritis Patients with an Inadequate Response to Various Combination Therapies. Intern Med. 2017;56(10):1147-52. 19. Ikeda K, Nakajima S, Tanji K, Hirai T, Uomori K, Morimoto S, Tomita S, Fukunaga M, Tamura N, Sekigawa I. Intestinal perforation due to hemorrhagic Cytomegalovirus enteritis in a patient with severe uncontrolled lupus nephritis: a case and review of the literature. Rheumatol Int. 2017;37(8):1395-9. 20. Ikeda K, Hayakawa K, Fujishiro M, Kawasaki M, Hirai T, Tsushima H, Miyashita T, Suzuki S, Morimoto S, Tamura N, Takamori K, Ogawa H, Sekigawa I. JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation. BMC Immunol. 2017;18(1):41. 21. Hirai T, Ikeda K, Fujishiro M, Tsushima H, Hayakawa K, Suzuki S, Yamaguchi A, Nozawa K, Morimoto S, Takasaki Y, Ogawa H, Takamori K, Tamura N, Sekigawa I. The effectiveness of new triple combination therapy using synthetic disease-modifying anti-rheumatic drugs with different pharmacological function against rheumatoid arthritis: the verification by an in vitro and clinical study. Clin Rheumatol. 2017;36(1):51-8.

研究テーマ

膠原病、特に全身性エリテマトーデスの病態における免疫機構の解析

研究業績（論文）

１なし、２なし、３なし、４なし、５なし、
６．論文
1. Hatano R, Nakamura H, Yamamoto A, Otsuka H, Itoh T, Hosokawa N, Yu J, Ranjbar S, Hasegawa Y, Sato T, Dang NH, Ohnuma K, Morimoto S, Sekigawa I, Ishii T, Morimoto C. An abnormal increase in CD26(−)CD28(−) cytotoxic effector CD4 and CD8 T cell populations in patients with systemic lupus erythematosus. Int Immunol. 2025; 37(3):153–171.
2. Suzuki S, Otani T, Ikeda K, Tamura N, Morimoto S. Immunol Method. Additional benefits of belimumab in chronic phase of systemic lupus erythematosus and efficacy of tacrolimus combination therapy2024 Dec 27:1-7. doi: 10.1080/25785826.2024.2447629.
3. Suzuki S, Kataoka Y, Otani T, Taniguchi Y, Ikeda K, Tamura N, Morimoto S. Optimal time of
starting tocilizumab in acute phase of adult-onset Still's disease and comparison of its efficacy with that of methotrexate: a case series and a review of the literature Clin Rheumatol. 2024 43(3):1245-1251.
4. Hayakawa K, Fujishiro M, Yoshida Y, Kataoka Y, Sakuma S, Nishi T, Ikeda K, Morimoto S, Takamori K, Sekigawa I. Exposure of female NZBWF1 mice to imiquimod-induced lupus nephritis at an early age via a unique mechanism that differed from spontaneous onset.
Clin Exp Immunol. 2022 13;208(1):33-46.
5. Suzuki S, Ikeda K, Yamaji K, Tamura N, Morimoto S. Recurrence in long-term survivor of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis: case series and literature review Mod Rheumatol Case Rep. 2021 5(2):310-316.
6. Kogami M, Suzuki S, Nanjo Y, Ikeda K, Tamura N, Sasaki S, Morimoto S. Complication of coronavirus disease 2019 during remission induction therapy against anti-MDA5 antibody-positive dermatomyositis　Rheumatol Adv Pract. 2020 17;4(2):rdoi: 10.1093/rap/rkaa068.
7. Yoshida Y, Hayakawa K, Fujishiro M, Ikeda K, Tsushima H, Hirai T, Kawasaki M, Tominaga
M, Suga Y, Takamori K, Watanabe Y, Sekigawa I, Morimoto S. Social defeat stress exacerbates atopic dermatitis through downregulation of DNA methyltransferase 1 and upregulation of C-C motif chemokine receptor 7 in skin dendritic cells. Biochem Biophys Res Commun. 2020;529(4):1073-9.
8. Matsuoka Y, Morimoto S, Fujishiro M, Hayakawa K, Kataoka Y, Suzuki S, Ikeda K,
Takamori K, Yamaji K, Tamura N. Metformin repositioning in rheumatoid arthritis. Clin Exp Rheumatol. 2020.
9. Hayakawa K, Kawasaki M, Hirai T, Yoshida Y, Tsushima H, Fujishiro M, Ikeda K, Morimoto
S, Takamori K, Sekigawa I. MicroRNA-766-3p Contributes to Anti-Inflammatory Responses through the Indirect Inhibition of NF-kappaB Signaling. Int J Mol Sci. 2019;20(4).
10. Niimi N, Miyashita T, Tanji K, Hirai T, Watanabe K, Ikeda K, Morimoto S, Sekigawa I. Aortic
Aneurysm as a Complication of Granulomatosis with Polyangiitis Successfully Treated with Prednisolone and Cyclophosphamide: A Case Report and Review of the Literature. Case Rep Rheumatol. 2018;2018:9682801.
11. Ikeda K, Sekiguchi N, Hirai T, Tanji K, Zushi A, Inoue M, Takasago M, Komatsu T,
Morimoto S, Yamaji K, Takamori K, Tamura N, Sekigawa I. Securely collecting multidimensional health information from patients with rheumatoid arthritis using smart device technology: Beneficial effect for physicians and patients. Musculoskeletal Care. 2018;16(4):494-9.
12. Hirai T, Ikeda K, Tsushima H, Fujishiro M, Hayakawa K, Yoshida Y, Morimoto S, Yamaji K,
Takasaki Y, Takamori K, Tamura N, Sekigawa I. Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis. Inflamm Regen. 2018;38:1.
13. Hayakawa K, Ikeda K, Fujishiro M, Yoshida Y, Hirai T, Tsushima H, Miyashita T, Morimoto
S, Suga Y, Takamori K, Ogawa H, Sekigawa I. Connective Tissue Growth Factor Neutralization Aggravates the Psoriasis Skin Lesion: The Analysis of Psoriasis Model Mice and Patients. Ann Dermatol. 2018;30(1):47-53.
14. Tsushima H, Morimoto S, Fujishiro M, Yoshida Y, Hayakawa K, Hirai T, Miyashita T, Ikeda
K, Yamaji K, Takamori K, Takasaki Y, Sekigawa I, Tamura N. Kinase inhibitors of the IGF-1R as a potential therapeutic agent for rheumatoid arthritis. Autoimmunity. 2017;50(5):329-35.
15. Sugiura-Ogasawara M, Omae Y, Kawashima M, Toyo-Oka L, Khor SS, Sawai H, Horita T,
Atsumi T, Murashima A, Fujita D, Fujita T, Morimoto S, Morishita E, Katsuragi S, Kitaori T, Katano K, Ozaki Y, Tokunaga K. The first genome-wide association study identifying new susceptibility loci for obstetric antiphospholipid syndrome. J Hum Genet. 2017;62(9):831-8.
16. Miyashita T, Morimoto S, Honda D, Nakano S, Amano H, Osawa I, Yamaji K, Tomino Y,
Takasaki Y, Tamura N. Outcomes of the Re-classification of WHO Class IV Lupus Nephritis Using the ISN/RPS Classification: a Single Center Retrospective Observational Study from the JUDE Study. Juntendo Medical Journal. 2017;63(5):362-9.
17. Minowa K, Amano H, Ando S, Watanabe T, Ogasawara M, Kawano S, Kaneko T, Morimoto
S, Yamaji K, Tamura N, Tokano Y, Hashimoto H, Takasaki Y. Disease flare patterns and predictors of systemic lupus erythematosus in a monocentric cohort of 423 Japanese patients during a long-term follow-up: The JUDE study. Mod Rheumatol. 2017;27(1):72-6.
18. Ikeda K, Watanabe K, Hirai T, Tanji K, Miyashita T, Nakajima S, Uomori K, Morimoto S,
Takamori K, Ogawa H, Takasaki Y, Sekigawa I. Mizoribine Synchronized Methotrexate Therapy should be Considered when Treating Rheumatoid Arthritis Patients with an Inadequate Response to Various Combination Therapies. Intern Med. 2017;56(10):1147-52.
19. Ikeda K, Nakajima S, Tanji K, Hirai T, Uomori K, Morimoto S, Tomita S, Fukunaga M,
Tamura N, Sekigawa I. Intestinal perforation due to hemorrhagic Cytomegalovirus enteritis in a patient with severe uncontrolled lupus nephritis: a case and review of the literature. Rheumatol Int. 2017;37(8):1395-9.
20. Ikeda K, Hayakawa K, Fujishiro M, Kawasaki M, Hirai T, Tsushima H, Miyashita T, Suzuki S,
Morimoto S, Tamura N, Takamori K, Ogawa H, Sekigawa I. JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation. BMC Immunol. 2017;18(1):41.
21. Hirai T, Ikeda K, Fujishiro M, Tsushima H, Hayakawa K, Suzuki S, Yamaguchi A, Nozawa K,
Morimoto S, Takasaki Y, Ogawa H, Takamori K, Tamura N, Sekigawa I. The effectiveness of new triple combination therapy using synthetic disease-modifying anti-rheumatic drugs with different pharmacological function against rheumatoid arthritis: the verification by an in vitro and clinical study. Clin Rheumatol. 2017;36(1):51-8.

研究者

教育活動

【学校法人順天堂】研究者情報データベース

研究業績詳細

森本 真司（モリモト シンジ）

森本真司（モリモトシンジ）